In the BioHarmony Drug Report Database
Lanadelumab
Takhzyro (lanadelumab) is an antibody pharmaceutical. Lanadelumab was first approved as Takhzyro on 2018-08-23. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against plasma kallikrein.
Trade Name
|
Takhzyro |
|---|---|
Common Name
|
lanadelumab |
ChEMBL ID
|
CHEMBL3545189 |
Indication
|
hereditary angioedemas |
Drug Class
|
Monoclonal antibodies: fully human, immunomodulating |
Image (chem structure or protein)
